Mercy Hospital
Welcome,         Profile    Billing    Logout  
 20 Trials 
38 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sleckman, Bethany G
NCT01041703: Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Recruiting
3
747
US, RoW
clofarabine, cytarabine, daunorubicin hydrochloride, decitabine
Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
Leukemia
02/19
 
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT01595048 / 2010-019224-31: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia

Active, not recruiting
2/3
640
US, Canada, RoW
Rituximab, MOAB IDEC-C2B8, Prednisone, Etoposide, Lastet, Doxorubicin Hydrochloride, Cytarabine, CHX-3311, U-19920, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Methotrexate, Methylprednisolone, MePRDL, Leucovorin Calcium, CF, Therapeutic Hydrocortisone, Aeroseb-HC, Cetacort, HC, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma
12/20
12/20
NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Recruiting
N/A
160
US
Observation
Tempus AI
Colorectal Cancer
02/25
02/27
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
813
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/25
02/27
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Recruiting
N/A
1050
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/24
05/25
NCT00904241: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Recruiting
N/A
10000
Europe, Canada, US, RoW
Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
01/00
 
NCT00736749: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Recruiting
N/A
5000
US
Assessment of Therapy Complications, Questionnaire Administration
Children's Oncology Group, National Cancer Institute (NCI)
Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
01/00
 
Pollack, Jonathan
VICToRY, NCT04138394: VItamin C in Thermal injuRY: The Trial

Recruiting
3
666
Europe, Canada, US, RoW
Ascorbic Acid, vitamin C, placebo, saline, D5W
Clinical Evaluation Research Unit at Kingston General Hospital, Dr. Christian Stoppe, MD, Co-Principal Investigator, Wurzburg University, Wurzburg, Germany
Shock, Thermal Burn
12/26
06/27
Thomas, Anish
NCT04162041: Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer

Recruiting
2
12
US
Topotecan + M6620, Topotecan
National Cancer Institute (NCI)
Carcinoma, Small Cell, Solid Tumors, SCLC, Extrapulmonary Lung Cancer, Relapse
06/22
12/22
NCT03896503: Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Active, not recruiting
2
81
US
Berzosertib, 2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-, M 6620, M6620, VX 970, VX-970, VX970, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI)
Bladder Small Cell Neuroendocrine Carcinoma, Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Recurrent Lung Small Cell Carcinoma
12/22
01/25
NCT04538378: Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Recruiting
2
25
US
Olaparib, Durvalumab
National Cancer Institute (NCI)
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
12/25
12/26
NCT02487095: Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

Active, not recruiting
1/2
62
US
Topotecan, Hycamtin, VX-970 (M6620), M6620
National Cancer Institute (NCI)
Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms, Carcinoma, Neuroendocrine, Extrapulmonary Small Cell Cancer
02/21
10/25
NCT04209595: PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

Active, not recruiting
1/2
10
US
PLX038, PEGylated SN38, Rucaparib, Rubraca, Ondansetron, Zofran
National Cancer Institute (NCI)
Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas
08/21
12/24
NCT03221400: PEN-866 in Patients With Advanced Solid Malignancies

Recruiting
1/2
340
US
PEN-866 Sodium, fluorouracil, 5-Fluorouracil, 5-FU, Folinic acid, Leucovorin, Niraparib, Zejula
Tarveda Therapeutics
Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
01/23
06/23
NCT03554473: M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Recruiting
1/2
80
US
M7824, Topotecan, Temozolomide
National Cancer Institute (NCI)
Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
01/25
01/25
NCT02769962: Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Hourglass Jan 2017 - Dec 2017 : Initial results of CRLX101 in combination with olaparib in advanced solid tumors
Hourglass Jan 2017 - Jun 2017 : Topline data from trial for solid tumors
Recruiting
1/2
123
US
EP0057, olaparib
National Cancer Institute (NCI)
Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms, Small Cell Lung Cancer, Prostate Cancer
07/25
12/27
NCT04802174: Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Recruiting
1/2
120
US
Lurbinectedin, Berzosertib
National Cancer Institute (NCI)
SCLC, Small Cell Cancer, Advanced Solid Tumor, High Grade Neuroendocrine Cancers
08/26
12/27
NCT04826341: A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Suspended
1/2
13
US
Berzosertib, Sacituzumab Govitecan
National Cancer Institute (NCI)
HRD Cancer, SCLC, Advanced Solid Tumors
03/26
03/27
NCI-2022-03215, NCT05353439: Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Recruiting
1
60
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Tazemetostat Hydrobromide, EPZ-6438 Monohydrobromide, Tazemetostat Monohydrobromide, TAZVERIK, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
04/25
04/25
C-Guardians, NCT04900844: Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting

Recruiting
N/A
315
Europe, US
CGuard Carotid Stent implantation, Carotid stenting
InspireMD
Carotid Artery Stenosis
07/22
10/25
RESTOR-1, NCT04663867: AngioSafe Peripheral CTO Crossing System Study ( Study)

Recruiting
N/A
100
US
AngioSafe Peripheral CTO Crossing System
AngioSafe, Inc., Veranex, Inc.
Peripheral Artery Occlusion, Peripheral Arterial Disease
02/23
02/23
NCT05132361: SELUTION4SFA Trial

Recruiting
N/A
300
Europe, US, RoW
SELUTION SLR™ 018 DEB, Plain (Uncoated) Balloon Angioplasty (PTA)
MedAlliance, LLC, NAMSA
Peripheral Arterial Disease, Superficial Femoral Artery Stenosis
12/24
12/29
NCT01851395: Rapid Autopsy and Procurement of Cancer Tissue

Recruiting
N/A
275
US
National Cancer Institute (NCI)
Thymus Tumors, Adoptive Cellular Therapy, Mesothelioma, Genitourinary Cancers, Lung Cancers
03/26
 
Mechem, Carol
C-Guardians, NCT04900844: Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting

Recruiting
N/A
315
Europe, US
CGuard Carotid Stent implantation, Carotid stenting
InspireMD
Carotid Artery Stenosis
07/22
10/25
Black, Jessica
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Recruiting
N/A
160
US
Observation
Tempus AI
Colorectal Cancer
02/25
02/27
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
813
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/25
02/27
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Recruiting
N/A
1050
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/24
05/25
Bansal, Vibhav
MOST, NCT03735979: Multi-arm Optimization of Stroke Thrombolysis

Active, not recruiting
3
514
US
Argatroban, Eptifibatide, Placebo
Washington University School of Medicine, National Institute of Neurological Disorders and Stroke (NINDS)
Acute Ischemic Stroke
12/23
04/25
ASPIRE, NCT03907046: Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Recruiting
3
700
US
Apixaban, Eliquis, Aspirin
Yale University, National Institute of Neurological Disorders and Stroke (NINDS)
Intracerebral Hemorrhage, Atrial Fibrillation
04/27
04/27
CREST-H, NCT03121209: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics

Recruiting
3
385
Canada, US
Revascularization, Intensive Medical Management (IMM) alone
Columbia University, National Institute of Neurological Disorders and Stroke (NINDS), Mayo Clinic, University of Alabama at Birmingham, University of Maryland, University of California, Los Angeles
Internal Carotid Artery Stenosis, Cognitive Impairment
01/27
07/27
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Recruiting
3
1683
US
Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management
University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca
Intracranial Arteriosclerosis, Stroke
05/27
05/27
CREST-2, NCT02089217: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

Recruiting
N/A
2480
Europe, Canada, US, RoW
Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS
Thomas G. Brott, M.D., National Institute of Neurological Disorders and Stroke (NINDS)
Carotid Stenosis
02/26
02/26
Westfall, Scott
CREST-H, NCT03121209: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics

Recruiting
3
385
Canada, US
Revascularization, Intensive Medical Management (IMM) alone
Columbia University, National Institute of Neurological Disorders and Stroke (NINDS), Mayo Clinic, University of Alabama at Birmingham, University of Maryland, University of California, Los Angeles
Internal Carotid Artery Stenosis, Cognitive Impairment
01/27
07/27
CREST-2, NCT02089217: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

Recruiting
N/A
2480
Europe, Canada, US, RoW
Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS
Thomas G. Brott, M.D., National Institute of Neurological Disorders and Stroke (NINDS)
Carotid Stenosis
02/26
02/26
Mantese, Annamarie
NCT04648293: Starling Registry Study

Completed
N/A
1207
US
Starling
Baxter Healthcare Corporation
Hemodynamic Monitoring
02/24
02/24
CREST-2, NCT02089217: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

Recruiting
N/A
2480
Europe, Canada, US, RoW
Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS
Thomas G. Brott, M.D., National Institute of Neurological Disorders and Stroke (NINDS)
Carotid Stenosis
02/26
02/26

Download Options